ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

glofitamab

Also written as “Glofitamab” and “IV Glofitamab”.

Its studies are mostly in Lymphoma · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell, led by Hoffmann-La Roche.

Drug pageGlofitamab: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 26, 202013 company-led studies, 9 open or runningNext primary completion: Mar 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche139 open or runningphase 3since May 26, 2020Mar 7, 2017Mar 22, 2027phase 1 · NCT06624085

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 7, 2017First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT03075696 · 940 enrolled · United States, Australia, Belgium and more
  2. Jun 9, 2019Named glofitamabINNProposed as its International Nonproprietary Name in WHO's List 121
  3. Mar 17, 2020Phase 1 study in Lymphoma, B-CellNCT04313608 · 23 enrolled · Australia
  4. May 26, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638 · 270 enrolled · United States, Australia, Belgium and more
  5. Dec 1, 2020Phase 1 study in LymphomaNCT04657302 · 30 enrolled · China
  6. Jul 19, 2021Phase 2 study in LymphomaNCT04980222 · 46 enrolled · United States, Denmark, France and more
  7. Nov 23, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05219513 · 53 enrolled · United States, Australia, Denmark and more
  8. Dec 13, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05169515 · 121 enrolled · United States, Israel, Italy and more
  9. May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05364424 · 43 enrolled · United States
  10. Sep 6, 2022Phase 2 study in RecurrenceNCT05533775 · 65 planned · United States, Australia, Brazil and more
  11. Sep 14, 20232 phase 3 studiesNCT06084936, NCT06047080
  12. Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico
  13. Jan 21, 2025Phase 2 study in RecurrenceNCT06806033 · 130 planned · United States, Australia, Canada and more
  14. Nov 10, 2026Primary completion moved from 2027-01-31 to 2029-07-31Date moved laterphase 2 · +30 months · NCT06806033

Ahead

  1. Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085
  2. Aug 31, 2027Primary completion: phase 3 study in LymphomaNCT06084936
  3. Oct 1, 2027Primary completion: phase 3 study in Large B-Cell LymphomaNCT06047080
  4. Mar 31, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638

TargetBeta

CD3E →MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06806033Recurrence · United States, Australia, Canada and more2RecruitingJul 31, 2029130
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingMar 22, 202750
NCT06084936Lymphoma · United States, Australia, Brazil and more3RecruitingAug 31, 2027182
NCT06047080Large B-Cell Lymphoma · United States, Argentina, Australia and more3Active, not recruitingOct 1, 20271,130
NCT05533775Recurrence · United States, Australia, Brazil and more2RecruitingNov 30, 202965
NCT05364424Lymphoma, Large B-Cell, Diffuse · United States1CompletedOct 15, 202543
NCT05169515Lymphoma, Non-Hodgkin · United States, Israel, Italy and more1Active, not recruitingApr 30, 2029121
NCT05219513Lymphoma, Non-Hodgkin · United States, Australia, Denmark and more1TerminatedJul 17, 202453
NCT04980222Lymphoma · United States, Denmark, France and more2Active, not recruitingOct 24, 202446
NCT04657302Lymphoma · China1CompletedOct 25, 202230
NCT04408638Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3Active, not recruitingMar 31, 2028270
NCT04313608Lymphoma, B-Cell · Australia1CompletedOct 26, 202123
NCT03075696Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2Active, not recruitingMar 30, 2029940

How it is read

Names in the registry

  • “Glofitamab”, 12 entries
  • “IV Glofitamab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.